Schatzberg's Manual of Clinical Psychopharmacology

Provides a thorough understanding of evolving treatments and medications. Blending evidence-based information with practical, real-world experience, this accessible volume examines the efficacy, dosing, and side effects of drug classes such as antidepressants, antipsychotic medications, mood stabilizers, and stimulants. Key features of this edition include the following: Updated information on newly FDA-approved agents such as vesicular monoamine transporter type-2 inhibitors for tardive dyskinesia, as well as those in late-stage review. A new chapter on pharmacogenomic testing and other commercially available tests designed to help clinicians select appropriate medications for their patients. Quick-reference summary tables on psychotropic classes for swift access to essential information, facilitating informed decision-making in clinical practice. A comprehensive list of suggested readings for each chapter, opening the door to further study and exploration. Additional sections also discuss approaches to treatment-resistant disorders, pharmacotherapy for substance use disorders, and working in specific settings and with special populations—including emergency department treatment and treating pregnant patients, children, and individuals from minority and marginalized communities. With its unrivaled wealth of information, Schatzberg’s Manual of Clinical Psychopharmacology remains a trusted, indispensable resource for clinicians seeking the latest advancements in psychopharmacology, arming them with the knowledge they will need to navigate with confidence the intricacies of psychotropic medications.

Provides a thorough understanding of evolving treatments and medications. Blending evidence-based information with practical, real-world experience, this accessible volume examines the efficacy, dosing, and side effects of drug classes such as antidepressants, antipsychotic medications, mood stabilizers, and stimulants. Key features of this edition include the following: Updated information on newly FDA-approved agents such as vesicular monoamine transporter type-2 inhibitors for tardive dyskinesia, as well as those in late-stage review. A new chapter on pharmacogenomic testing and other commercially available tests designed to help clinicians select appropriate medications for their patients. Quick-reference summary tables on psychotropic classes for swift access to essential information, facilitating informed decision-making in clinical practice. A comprehensive list of suggested readings for each chapter, opening the door to further study and exploration. Additional sections also discuss approaches to treatment-resistant disorders, pharmacotherapy for substance use disorders, and working in specific settings and with special populations—including emergency department treatment and treating pregnant patients, children, and individuals from minority and marginalized communities. With its unrivaled wealth of information, Schatzberg’s Manual of Clinical Psychopharmacology remains a trusted, indispensable resource for clinicians seeking the latest advancements in psychopharmacology, arming them with the knowledge they will need to navigate with confidence the intricacies of psychotropic medications.